Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer and Coley will seek an indication for first-line treatment of advanced non-small cell lung cancer for their toll-like receptor agonist ProMune (CPG 7909)
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class